Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report

Danuta Krasowska, Aleksandra Szczepnek, Magdalena Kozioł, Ewa Szczepanek-Wąsik

DOI: http://dx.doi.org/10.12775/JEHS.2020.10.09.034

Abstract


Mantle cell lymphoma is a rare subtype of non- Hodgkin lymphoma with life-threatening course of disease. It mostly affects older adults in their sixth or seventh decade of life with male to female predominance of 3 to 1. It prognosis is very poor and the treatment is demanding. The golden standard therapy for younger, fit patients <65 years is chemoimmunotherapy such as R-CHOP/R-DHAP rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisolone, dexamethasone, cytarabine and cisplatin) followed by BEAM chemotherapy (carmustine, etoposide, cytarabine, melphalan)  and autologous- stem-cell transplant (ASCT).  Nevertheless MCL is mainly recognized in patients of average age 67 in whom comorbidities often play a crucial role during treatment.

A 56- years old patient was admitted to the Department of Hematooncology and Bone Marrow Transplantation with clinical symptoms such as heavy night sweats, generalized enlargement of lymph nodes, massive weight loss, dyspnea and fatigue. Initial physical examination and imaging showed enormous hepatosplenomegaly, mass in the lungs and fluid in the pleural cavity.

The patients underwent chemioimmunotherapy consolidated with an autologous stem cell transplant. To date, the patient is on maintenance treatment with ibrutinib.


Keywords


mantle cell lymphoma; ibrutinib; maintenance therapy

Full Text:

PDF

References


Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647-1656. doi:10.1182/blood-2018-03-791392

Parrott M, Rule S. Does maintenance therapy have a role in mantle cell lymphoma treatment?. Expert Rev Hematol. 2018;11(4):285-292. doi:10.1080/17474086.2018.1449635

Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2018;181(5):703-706. doi:10.1111/bjh.14699

Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantlecell lymphoma. N Engl J Med. 2017;377:1250–1260

Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood. 2013;121:48–53

Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–5675

Brian G, Till MD. Maintance therapy in diffuse large B-cell lymphoma and mantle cell lymphoma. Curr Treat Options in Oncol. 2018; 19-45

Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1995;13:2819–2826

Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005;23:705–711

Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003–4008

Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–531

Ahmadi T, McQuade J, Porter D, et al. Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. Bone Marrow Transplant. 2012;47:1082–1086.

Graf SA, Stevenson PA, Holmberg LA, et al. Maintenance rituximab afterautologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol. 2015;26:2323–2328.

Mei MG, Cao TM, Chen L, et al. Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab. Biol Blood Marrow Transplant. 2017;23:1861–1869

Barth MJ, Mavis C, Czuczman MS, et al. Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in preclinical models of mantle cell lymphoma. Clin. Cancer Res. 2015, 21: 4391–4397

Heinrich DA, Weinkauf M, Hutter G, et al. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma. Br. J. Haematol. 2015, 168: 606–610

Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (ga101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: Results from the phase II gauguin study. J. Clin. Oncol. 2013, 31: 2912–2919

Furtado M, Dyer MJ, Johnson R, et al. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma—A phase II trial. Br. J. Haematol. 2014, 165: 575–578

Mondello P, Steiner N, Willenbacher W, et. al. 90y-ibritumomab-tiuxetan consolidation therapy for advanced-stage mantle cell lymphoma after first-line autologous stem cell transplantation: Is it time for a step forward? Clin. Lymphoma Myeloma Leuk. 2016, 16: 82–88

Kaplan LD. Jung SH. Stock W. Bartlett, et al. Bortezomib maintenance (bm) versus consolidation (bc) following aggressive immunochemotherapy and autologous stem cell transplant (asct) for untreated mantle cell lymphoma (mcl): Calgb (alliance) 50403. Blood 2015, 126, 337.

Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516

Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 2016; 387: 770–778.

Skarzynski M, Niemann CU, Lee YS, et al. Interactions between ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy. Clin Cancer Res 2016; 22: 86–95

Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014; 123: 1957–1960

Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet 2018;5: 109-116

Yan F, Gopal AK, Graf S. Targeted drugs as maintenance therapy after autologous stem cell transplantation in patients with mantle cell lymphoma. Pharmaceuticals 2017, 10: 1-11.


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM




Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

https://pbn.nauka.gov.pl/sedno-webapp/search?search&searchCategory=WORK&filter.inJournal=36616

POL-index 2011 - 2014

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-32a319c5-a850-4f44-ba70-1418a6087655

BASE 2011 - 2014

https://www.base-search.net/Search/Results?lookfor=Journal+of+Health+Sciences+%28Radom%29&type=all&oaboost=1&ling=1&name=&thes=&refid=dcrespl&newsearch=1

http://elibrary.ru/contents.asp?titleid=37467

http://journal.rsw.edu.pl/index.php/JHS/issue/archive

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska, EuroPub database, NLM Catalog Result - NCBI, BASE, Russian Sciences Index, Arianta.

https://zdb-katalog.de/title.xhtml?idn=1080187162

https://europub.co.uk/journals/22625

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

https://www.ncbi.nlm.nih.gov/nlmcatalog/101679844

Find a library that holds this journal: http://worldcat.org/issn/23918306

 

PBN Poland

https://pbn.nauka.gov.pl/sedno-webapp/journals/49068

POL-index

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-c39c8169-88d2-45db-9e7f-d948ce9981c4

BASE

https://www.base-search.net/Search/Results?join=AND&bool0[]=AND&lookfor0[]=2391-8306&type0[]=all&page=11&l=pl&oaboost=1&refid=dcpagepl

Redaction, Publisher and Editorial Office

Publisher and Editorial Office
Department of Physical Culture,
Faculty of Earth Sciences and Spatial Management,
Nicolaus Copernicus University in Toruń, Poland
Address: Str. Lwowska 1, 87-100 Toruń, Poland

  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at https://dbh.nsd.uib.no/publiseringskanaler/erihplus/periodical/info?id=485984

Indexed in Index Copernicus Journals Master List.

http://journals.indexcopernicus.com/Journal+of+Education+Health+and+Sport,p24782242,3.html

ICV 2019 = 100.00 ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

RG Journal Impact: 0.18 *

*This value is calculated using ResearchGate data and is based on average citation counts from work published in this journal. The data used in the calculation may not be exhaustive.

RG Journal impact history

2020Available summer 2021
2018 / 20190.18
20170.07
20160.03

RG Journal impact over time

RG Journal impact
0.180.160.140.120.100.080.060.040.02201620172018
  

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (https://pbn.nauka.gov.pl/journals/36616)

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ) http://elibrary.ru/contents.asp?titleid=37467

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski

(http://www1.bg.us.edu.pl/bazy/czasopisma/czasop_full.asp?id=3595)

Partnerzy platformy czasopism